Fintel reports that on April 2, 2025, Lake Street initiated coverage of OS Therapies (NYSEAM:OSTX) with a Buy recommendation. Analyst Price Forecast Suggests 865.16% Upside As of March 19, 2025, the ...

OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported full-year 2024 financial ...

NEW YORK, March 31, 2025--OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today ...

Explore OS Therapies stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for OSTX. Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer ...

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are ...

Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical ...

OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that Paul Romness ...

OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...

Patients with metastatic NSCLC may benefit from continuing on pembrolizumab-based treatment after progressing on that ...

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

In this article, we are going to take a look at where OS Therapies Incorporated (NYSEAMERICAN:OSTX) stands against other penny stocks with the biggest upside potential. Penny stocks trade below $5 ...